METHOD AND APPARATUS FOR RECOVERY OF AMINE FROM AMINE-CONTAINING WASTE WATER AND REGENERATION OF CATION EXCHANGE RESIN

Provided is an apparatus for recovering amines from amine-containing waste water generated in power stations, etc., and regenerating a cation exchange resin. The apparatus includes: a cation exchange resin layer capturing amines from amine-containing waste water and eluting the amines therefrom; a degassing tower degassing the eluted amines; a vacuum pump connected to the degassing tower; and a condensation and cooling tower condensing the degassed amines at a temperature of −33° C. or lower, wherein the amines captured in the cation exchange resin layer are eluted by injecting a strong acidic solution, while the resin is regenerated, and the amines eluted by the strong acidic solution is subjected to vacuum degassing and then recovered. Provided also is a method for recovering amines and regenerating a cation exchange resin using the apparatus. The apparatus and method for recovering amines and regenerating a cation exchange resin improve the quality of effluent water from power stations, etc., and increase the cost-efficiency through the recycle of amines. 1. An apparatus for recovering amines from amine-containing waste water and regenerating a cation exchange resin , comprising:a cation exchange resin layer capturing amines from amine-containing waste water and eluting the amines therefrom;a degassing tower degassing the eluted amines;a vacuum pump connected to the degassing tower;a condensation and cooling tower condensing the degassed amines at a temperature of −33° C. or lower; andan adsorption tower capturing at least one selected from the group consisting of water and amines,wherein the amines captured in the cation exchange resin layer are eluted by injecting a strong acidic solution, while the resin is regenerated as a hydrogen-form cation exchange resin, and the amines eluted by the strong acidic solution are subjected to vacuum degassing and then recovered.2. The apparatus for recovering amines according to claim 1 , wherein the cation exchange resin ...

METHOD FOR REMOVING DEPOSITED SLUDGE

Provided is a physical and chemical cleaning method, including introducing nitrogen gas, liquid nitrogen or dry ice into a cleaning solution containing at least one selected from the group consisting of water, monoethanolamine (ETA), dimethylamine (DMA), NH, ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA) and NHto remove sludge. The physical and chemical cleaning method is capable of removing sludge, generated or deposited on the substrate surfaces, surfaces of constitutional parts, or gaps in various systems and instruments, more effectively. The physical and chemical cleaning method may be applied to cleaning of steam generators, boilers, heat exchangers, or the like, used in atomic power stations. 1. A physical and chemical cleaning method for removing sludge , comprising:soaking a subject, from which sludge is to be removed, into a cleaning solution;causing a change in temperature and pressure of the cleaning solution and forming bubble in the cleaning solution; andincreasing the temperature of the subject to facilitate the removal of the sludge.2. The physical and chemical cleaning method for removing sludge according to claim 1 , wherein the sludge is sludge formed in atomic power stations.3. The physical and chemical cleaning method for removing sludge according to claim 1 , wherein the cleaning solution contains at least one selected from the group consisting of water claim 1 , monoethanolamine (ETA) claim 1 , NH claim 1 , ethylenediaminetetraacetic acid (EDTA) claim 1 , diethylenetriaminepentaacetic acid (DTPA) and NH.4. The physical and chemical cleaning method for removing sludge according to claim 1 , wherein the causing a change in temperature and pressure of the cleaning solution and forming bubble in the cleaning solution is carried by introducing at least one selected from a group consisting of nitrogen gas claim 1 , liquid nitrogen and dry ice to the cleaning solution to cause a change in temperature and pressure ...

SOAP COMPOSITION FOR TREATING ACNE CONTAINING ABSOLUTE GINSENG ESSENTIAL OIL

The present invention discloses a soap composition containing a ginseng absolute oil, based on the finding that a ginseng extract, particularly a ginseng absolute oil, has a potent effect on the treatment of acne. A soap composition for treating acne according to one embodiment of the present invention was used, and as a result, it could be seen that the soap composition exhibited excellent effects of removing sebum and killing acne bacteria to prevent proliferation of the bacteria and infection with the bacteria, thus exhibiting a potent effect on the treatment of acne. 1. A soap composition for treating acne containing a ginseng absolute oil.2. The soap composition of claim 1 , wherein the ginseng absolute oil is contained in an amount of 0.01-5 wt % based on a total weight of the soap composition.3. The soap composition of claim 1 , wherein the composition is in a liquid claim 1 , cream claim 1 , paste or solid form.4Propionibacterium acnes. The soap composition of claim 1 , wherein the ginseng absolute oil has a bactericidal effect against acne bacteria ().5. The soap composition of claim 2 , wherein the composition is in a liquid claim 2 , cream claim 2 , paste or solid form.6Propionibacterium acnes. The soap composition of claim 2 , wherein the ginseng absolute oil has a bactericidal effect against acne bacteria (). The present invention relates to a soap composition for treating acne containing a ginseng absolute oil.Generally, acne is an inflammation of hair follicles on the face, particularly the cheek and the forehead, and often occurs in adolescent men and women. Acne occurs when the secretion of hormones such as androgens increases. Androgens enlarge and stimulate the sebaceous glands, causing them to produce more sebum. Acne arises when the sebaceous glands become clogged due to hyperkeratinization of hair follicles. When the sebaceous glands become clogged, the sebum is accumulated below the skin, and the hair follicle blows up like a balloon and ...

FABRICATION METHOD OF A NOVEL ARTIFICIAL CORTICAL BONE USING A MULTI-PASS EXTRUSION PROCESS

A method for fabricating an artificial bone by multi-pass extrusion, includes: a first extrusion process of forming roll-shaped filaments having sheets of calcium phosphate/calcium phosphate-(t-ZrO)/t-ZrO; a second extrusion process of arranging the prepared roll-shaped filaments circularly and extruding the same; and a third extrusion process of forming an external shell of hydroxyapatite (HAp). The method for fabricating an artificial bone allows fabrication of an artificial bone having the biocompatibility and mechanical strength of the natural bone and may be utilized variously in biomedical engineering, medicine and other applications. 1. A method for fabricating an artificial bone by multi-pass extrusion , comprising:{'sub': 2', '2, 'a first extrusion process of forming roll-shaped filaments comprising sheets of calcium phosphate/calcium phosphate-(t-ZrO)/t-ZrO;'}a second extrusion process of arranging the prepared roll-shaped filaments circularly and extruding the same; anda third extrusion process of forming an external shell of hydroxyapatite (HAp).2. The method for fabricating an artificial bone by multi-pass extrusion according to claim 1 , wherein the calcium phosphate is hydroxyapatite (HAp) or tricalcium phosphate (TCP).3. The method for fabricating an artificial bone by multi-pass extrusion according to claim 1 , wherein claim 1 , in the second extrusion process claim 1 , carbon filaments are aligned at the center and the roll-shaped filaments are arranged to surround the carbon filaments.4. The method for fabricating an artificial bone by multi-pass extrusion according to claim 1 , which further comprises claim 1 , after the third extrusion process claim 1 , a burning out process and a sintering process.5. The method for fabricating an artificial bone by multi-pass extrusion according to claim 4 , which comprises claim 4 , after the third extrusion process:a first burning out process at 600-800° C.;a second burning out process at 900-1100° C.; anda ...

CENTRIFUGAL BLOWER

A centrifugal blower is designed such that D/R, which is a ratio of a radius D of an air inlet to a radius R of an impeller, ranges from 85% to 87%, and such that r/R, which is a ratio of a radius r of a cross-section of a bell mouth of the centrifugal blower to the radius R of the impeller, ranges from 8% to 10%. With such a structure, a geometric size of the bell mouth is optimized, thus enhancing the blowing efficiency of the centrifugal blower. As a result, superior performance of the centrifugal blower can be ensured. 1. A centrifugal blower , comprising:a scroll casing having an inlet port, formed in an upper surface of the scroll casing, and an outlet port formed in a side surface of the scroll casing;an impeller installed in the scroll casing, the impeller having a cylindrical shape, with a hub being disposed in the impeller such that the impeller is rotated by rotating the hub; anda bell mouth having a ring shape and disposed on an edge of the inlet port of the scroll casing, the bell mouth forming an air inlet of the scroll casing and having a semi-circular cross-section,wherein D/R, which is a ratio of a radius (D) of the air inlet to a radius (R) of the impeller, ranges from 85% to 87%.2. The centrifugal blower as set forth in claim 1 , wherein r/R claim 1 , which is a ratio of a radius (r) of the cross-section of the bell mouth to the radius (R) of the impeller claim 1 , ranges from 8% to 10%.3. The centrifugal blower as set forth in claim 1 , whereinD/R, which is the ratio of the radius (D) of the air inlet to the radius (R) of the impeller, is 86%, andr/R, which is a ratio of a radius (r) of the cross-section of the bell mouth to the radius (R) of the impeller, is 9%.4. The centrifugal blower as set forth in claim 2 , whereinD/R, which is the ratio of the radius (D) of the air inlet to the radius (R) of the impeller, is 86%, andr/R, which is the ratio of the radius (r) of the cross-section of the bell mouth to the radius (R) of the impeller, is 9%.5. ...

NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF

The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3′ OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders. 13.-. (canceled)7. The method of claim 6 , wherein the proliferative disorders are selected from the group consisting of inflammatory diseases claim 6 , cancer claim 6 , cardiovascular diseases claim 6 , allergy claim 6 , asthma and autoimmune disorders. This application is a divisional of U.S. patent application Ser. No. 13/423,950, filed Mar. 19, 2012, allowed, which claims the benefit of and priority to U.S. Provisional Patent Application No. 61/453,850, filed on Mar. 17, 2011. The contents of each of the foregoing applications are incorporated herein by reference in their entirety.This invention relates to a series of substituted pyridopyrimidine which are kinase inhibitors, especially inhibitors of the phosphoinositide 3′ OH kinase family (hereinafter PI3 Kinase; PI3Kα, PI3Kβ, PI3Kγ and/or PI3δ) for treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders. This invention also relates to a pharmaceutical composition comprising the compound of the invention, use of the compound in the preparation of a medicament, and method of treatment for hyperproliferative diseases in mammals, especially humans by administering the compound thereof.The phosphoinositide 3-kinases (PI3Ks) are a family of enzymes involved in cellular function such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. And the PI3Ks utilize both lipid and protein kinase activity to regulate numerous intracellular signal ...

STENT FOR THE COIL EMBOLIZATION OF A CEREBRAL ANEURYSM

Disclosed is a stent for the coil embolization of a cerebral aneurysm. The stent according to one embodiment of the present invention is shaped as a cylinder formed of a mesh-structured metal thin wire to enable a coil to fill the inside of said cerebral aneurysm through the mesh of the stent. And the stent has such a shape as the maximum diameter of the center portion of the stent is larger than the maximum diameter of each of both end portions of the stent. For example, the stent may have a fusiform shape in which the center portion protrudes further than the end portions. 1. A stent used for coil embolization of a cerebral aneurysm , wherein the stent is in a cylindrical shape made of a mesh-structured thin metal wire so as to help a coil to fill the cerebral aneurysm through a mesh of an outer surface of the stent , and a maximum diameter of a middle portion of the stent is greater than that of edge portions proximal to the middle portion.2. The stent of claim 1 , wherein the cylindrical shape is a fusiform shape such that the middle portion protrudes further than the both edge portions.3. The stent of claim 1 , wherein the cylindrical shape is a semi-fusiform shape such that one side of the middle portion protrudes further than the both edge portions.4. The stent of claim 3 , wherein the stent is curved on an opposite direction against a direction toward which the middle portion protrudes.5. The stent of claim 1 , wherein one or more protrusion markers made of radio-opacity materials are installed at the middle portion.6. The stent of claim 1 , wherein the middle portion has a length of between 4 mm and 40 mm.7. The stent of claim 1 , wherein the middle portion has a maximum diameter of between 2 mm and 8 mm.8. The stent of claim 1 , wherein the stent has a fallopian-tube shape such that each edge portion increases in a diameter from a proximal to distal direction.9. The stent of claim 1 , wherein a size of a mesh of each edge portion is smaller than that of a ...

Use of igf-1 as prognostic factor in calcification of aortic valves

The present disclosure relates to: a composition for diagnosing aortic valve calcification diseases, comprising a preparation, which measures the protein level of inactivated IGF-1, wherein the composition is capable of diagnosing aortic valve calcification diseases involving calcification of aortic valves; a kit for diagnosing aortic valve calcification diseases, comprising the composition; a method for detecting inactivated IGF-1 so as to provide information necessary in the diagnosis of aortic valve calcification diseases; and a method for detecting inactivated IGF-1 so as to provide information necessary in the diagnosis of the progression level of aortic valve calcification diseases. According to the present disclosure, when using the composition or the kit for diagnosing aortic valve calcification diseases, it is possible to determine whether aortic valve calcification diseases, which involve the calcification of aortic valves, have occurred, and to determine the progression level of aortic valve calcification diseases which have already occurred, and thus the composition or the kit of the present disclosure can be used for more effectively diagnosing and treating aortic valve calcification diseases.

PLANAR TYPE MAGIC TEE

A planar type magic tee includes a first coupling unit, a second coupling unit, and transmission lines for connecting the first coupling unit and the second coupling unit to each other in a cascading manner, the transmission lines having different characteristic impedances. The planar type magic tee is capable of solving the problem caused due to the intrinsic limitation in bandwidth of a conventional ring hybrid coupler. 1. A planar type magic tee comprising:a first coupling unit;a second coupling unit; andtransmission lines, through which the first coupling unit and the second coupling unit are connected to each other in a cascading manner in a planar state, the transmission lines having different characteristic impedances.2. The planar type magic tee according to claim 1 , wherein the transmission lines comprise:{'sub': 'A', 'a first conductor having impedance Zformed at the first coupling unit; and'}{'sub': 'B', 'a second conductor having impedance Zformed at the second coupling unit,'}the first conductor and the second conductor being connected to each other.3. The planar type magic tee according to claim 2 , wherein the first coupling unit and the second coupling unit are provided with ports having impedance Z. The present invention relates to a planar type magic tee, and more particularly to a planar type magic tee using 3 dB directional couplers and transmission lines.Coupling is a phenomenon in which alternating current signal energy is transmitted electromagnetically between separate spaces or lines.A coupler is a device that artificially adjusts the extent of such coupling and arbitrarily adjusts the length of lines and the distance between the lines so as to transmit desired power.A coupler is usually used in a wireless system. A four-port ring hybrid coupler is a basic microwave device that is widely used in a wireless system. An example of a four-port ring hybrid coupler is shown in .A conventional ring hybrid coupler is characterized in that two ...

Composition for Treatment or Metastasis Suppression of Cancers Which Includes P34 Expression Inhibitor or Activity Inhibitor as Active Ingredient

The present invention relates to a composition for treatment or metastasis suppression of cancers which includes a p34 expression inhibitor or activity inhibitor as an active ingredient. According to the present invention, the p34 protein knock-down causes monoubiquitination of PTEN and accordingly nuclear localization of PTEN is induced, as a result, an Akt pathway which is related to survival, proliferation, invasive properties and metastatic properties of tumors is inhibited, and thus there is an effect of significantly reducing clonogenic potential and tumor forming potential of various cancer cells which simultaneously express PTEN and NEDD4-1. Consequently, the p34 gene expression inhibitor or p34 protein activity inhibitor according to the present invention can be effectively used as a treatment agent or a metastasis suppression agent for cancers.

Monoclonal antibody specifically binding to ccsp-2 and use thereof

The present invention relates to a monoclonal antibody which specifically binds to an EGF2 domain of colon cancer secreted protein-2 (CCSP-2), or an antigen-binding fragment thereof. The monoclonal antibody or the antigen-binding fragment thereof of the present invention specifically binds to the EGF2 domain of CCSP-2, and thus has significantly increased affinity compared with existing peptides specifically binding to CCSP-2 and further increased specificity compared with existing antibodies to CCSP-2. Therefore, in future, accurate diagnosis can be achieved by specific detection of CCSP-2 in the protein level.

METHOD OF REFORMING METAL SURFACE OF COOLING OR CIRCULATING SYSTEM OF NUCLEAR OR THERMAL POWER PLANT

A method of reforming a metal surface of a cooling or circulating system of a nuclear or thermal power plant is provided. The method of reforming a metal surface of a cooling or circulating system of a nuclear or thermal power plant includes injecting metal ions or metal nanoparticles into a cooling or circulating system of a nuclear or thermal power plant (S), converting the injected metal ions into metal particles by a chemical reaction with hydrogen (H), hydrazine (NH), or amine in water (S), and forming an insulating layer or a catalyst layer by depositing metal particles or metal nanoparticles on a metal surface or an oxide coating film of the cooling or circulating system (S). 1. A method of reforming a metal surface of a cooling or circulating system of a nuclear or thermal power plant , comprising:{'b': '11', 'injecting metal ions or metal nanoparticles into a cooling or circulating system of a nuclear or thermal power plant (S);'}{'sub': 2', '2', '4, 'b': '12', 'converting the injected metal ions into metal particles by a chemical reaction with hydrogen (H), hydrazine (NH), or amine in water (S); and'}{'b': '13', 'forming an insulating layer or a catalyst layer by depositing metal particles or metal nanoparticles on a metal surface or an oxide coating film of the cooling or circulating system (S).'}2. The method according to claim 1 , wherein the metal ions or metal nanoparticles include at least one selected from the group consisting of Ti claim 1 , V claim 1 , Cr claim 1 , Ni claim 1 , Zn claim 1 , Y claim 1 , Zr claim 1 , Ru claim 1 , Rh claim 1 , Pd claim 1 , Ag claim 1 , In claim 1 , Sn claim 1 , Hf claim 1 , Ta claim 1 , W claim 1 , Os claim 1 , Ir claim 1 , Pt claim 1 , and Au.3. The method according to claim 1 , wherein a system injection concentration of the metal ions or metal nanoparticles is 10 ppm or less.4. The method according to claim 1 , wherein a concentration of the hydrogen (H) claim 1 , hydrazine (NH) claim 1 , or amine contained in ...

COMPOSITION COMPRISING ERIGERON ANNUUS FLOWER ESSENTIAL OIL FOR PREVENTION AND TREATMENT OF NEUROMUSCULAR DISEASE

Disclosed are a pharmaceutical composition and a beauty-purposed pharmaceutical composition for prevention or treatment of neuromuscular disease, the composition including a combination of flower-based essential oil and Botox. flower-based essential oil inhibits t-SNARE protein and v-SNARE protein expression in neurons to inhibit the formation of SNARE protein complexes. flower-based essential oil inhibits the regeneration of t-SNARE protein and v-SNARE protein degraded by Botox to inhibit neurotransmitter release. Accordingly, an efficacy duration of Botox may be extended. Thus, flower-based essential oil may be usefully used in combination with Botox as Botox adjuvant for the prevention and treatment of neuromuscular disease or for beauty. 1Erigeron annuus. A pharmaceutical composition for prevention or treatment of a neuromuscular disease , the composition including a combination of flower-based essential oil and Botox.2. The pharmaceutical composition of claim 1 , wherein the Botox acts to degrade a target membrane soluble N-ethylmaleimide-sensitive factor attachment protein receptor (t-SNARE) protein of a neuron membrane claim 1 , and a vesicle soluble N-ethylmaleimide-sensitive factor attachment protein receptor (v-SNARE) protein of a synaptic vesicle membrane claim 1 ,{'i': 'Erigeron annuus', 'wherein the flower-based essential oil acts to inhibit re-production of the t-SNARE protein and v-SNARE protein as degraded by Botox.'}3Erigeron annuus. The pharmaceutical composition of claim 1 , wherein the flower-based essential oil extends an efficacy duration of the Botox by 1.5 to 10 times.4. The pharmaceutical composition of claim 1 , wherein the neuromuscular disease is selected from the group consisting of muscle tension claim 1 , muscle cramp claim 1 , hemifacial spasm claim 1 , adult onset spasmodic torticollis claim 1 , anal fissures claim 1 , blepharospasm claim 1 , facial muscle spasms claim 1 , cerebral paralysis claim 1 , headache claim 1 , migraine ...

Blood cell-free dna-based method for predicting prognosis of liver cancer treatment

The present invention relates to a blood cell-free DNA-based method for predicting the prognosis of liver cancer treatment. A method for predicting the prognosis of liver cancer, according to the present invention, uses next generation sequencing (NGS) so as to increase the accuracy of prognosis prediction of a liver cancer patient and also increase the accuracy of prognosis prediction based on a very low concentration cell-free DNA of which detection has been difficult, thereby increasing the commercial utilization thereof. Therefore, the method of the present invention is useful for determining the prognosis of a liver cancer patient.

SYSTEM AND METHOD FOR DECENTRALIZING PUBLIC TRANSPORTATION PASSENGERS USING TRANSPORTATION CARD READER

Provided are a system and method for decentralizing public transportation passengers using a transportation card reader. The system includes a vehicle terminal including a transportation card reader counting the number of touches of transportation cards of riding and exiting passengers of a public transportation means and configured to transmit a count value to a center, an integrated database server provided in the center and configured to update a count value of each public transportation means with a transmitted count value of the public transportation means and transmit the updated count value to a station, a station terminal provided at the station and configured to display the updated and transmitted count value, and a mobile device configured to receive information on the riding and exiting passengers of the public transportation means from the integrated database server or the station terminal and output the received information. 1. A system for decentralizing public transportation passengers using a transportation card reader , comprising:a vehicle terminal including a transportation card reader counting the number of touches of transportation cards of riding and exiting passengers of a public transportation means, and configured to transmit a count value to a center;an integrated database server provided in the center, and configured to update a count value of each public transportation means with a transmitted count value of the public transportation means and transmit the updated count value to a station; anda station terminal provided at the station, and configured to display the updated and transmitted count value.2. The system of claim 1 , further comprising a mobile device configured to receive information on the riding and exiting passengers of the public transportation means from the integrated database server or the station terminal claim 1 , and output the received information.3. The system of claim 2 , wherein the integrated database server ...

GAMMA-RAY SENSING PROBE USING CERENKOV EFFECT AND SYSTEM FOR IDENTIFYING BURNUP OF SPENT NUCLEAR FUEL ASSEMBLY USING THE SAME

Provided are a gamma-ray sensing probe using the Cerenkov effect, and a system for identifying the burnup of a spent nuclear fuel assembly using the gamma-ray sensing probes, wherein the system is established using the gamma-ray sensing probe including: an optical fiber reacting to gamma rays coming from the spent nuclear fuel assembly by the Cerenkov effect and emitting light by itself; a scatterer surrounding the optical fiber to increase light emitting efficiency of the optical fiber by the Cerenkov effect; and a collimator configured to surround the scatterer and composed of a shielding material, the collimator having a slit groove which is open in one direction, whereby the burnup of the spent nuclear fuel assembly can be accurately determined. 1. A gamma-ray sensing probe using the Cerenkov effect , that is intended to sense gamma rays coming from a gamma-ray test surface of a spent nuclear fuel assembly in order to measure the gamma rays coming from a spent nuclear fuel , the gamma-ray sensing probe comprising:an optical fiber disposed to face a gamma-ray test surface of a spent nuclear fuel assembly in a direction perpendicular to a lengthwise direction of the spent nuclear fuel assembly, the optical fiber reacting to gamma rays coming from the gamma-ray test surface and emitting light by the Cerenkov effect;a scatterer extending to the extent of a length of the gamma-ray test surface and formed to surround an outer circumferential surface of the optical fiber, the scatterer reacting to gamma. rays incident from the gamma-ray test surface of the spent nuclear fuel assembly to the optical fiber and causing Compton scattering; anda collimator surrounding an outer circumferential surface of the scatterer and composed of a shielding material, the collimator having a slit groove formed at one side thereof, thereby passing only gamma rays coming from a part of the gamma-ray test surface, for which measurement is required, through the scatterer.2. The gamma-ray ...

Systems for monitoring the cardiovascular system using a heart lung sound

The present invention relates to A system for monitoring the cardiovascular system using a heart sound, which comprises a heart sound receiving means( 100 ) for receiving a heart sound(HS); DSP (Digital Signal Processor) module( 200 ) for converting the heart sound(HS) received from said heart-sound receiving means( 100 ) to a digital signal; and an arithmetic section( 300 ) for calculating phonocardiogram(PCG) from the digital signal converted in the DSP module ( 200 ) and calculating information related to a preload or information related to a cardiac contractile force or information related to a respiratory change.

TUMOR SURFACE DOSE ENHANCING RADIOTHERAPY APPARATUS USING MAGNETIC FIELD

Disclosed is a tumor surface dose enhancing radiotherapy apparatus using a magnetic field, including a radiation beam generating unit that irradiates a radiation beam towards a tumor of a patient, a magnetic field generating unit that forms a magnetic field that is parallel to the radiation beam between the radiation beam generating unit and the tumor of the patient, and a control unit that controls a surface dose of the tumor by adjusting an intensity and an effective area of the magnetic field of the magnetic field generating unit. 1. A tumor surface dose enhancing radiotherapy apparatus using a magnetic field , comprising:a radiation beam generating unit that irradiates a radiation beam toward a tumor of a patient; anda magnetic field generating unit that is arranged between the radiation beam generating unit and the tumor of the patient to form, around the radiation beam, a magnetic field that is parallel to the radiation beam,wherein the radiation beam travels in the magnetic field, andwherein the magnetic field generating unit forms a magnetic field area in a body cavity or a low-density space in a body.2. The tumor surface dose enhancing radiotherapy apparatus of claim 1 , further comprising:a control unit that controls a surface dose of the tumor by adjusting an intensity and an effective area of the magnetic field by the magnetic field generating unit,3. The tumor surface dose enhancing radiotherapy apparatus of claim 1 , wherein the magnetic field generating unit comprises a plurality of magnets that are arranged around the radiation beam while facing each other such that same polarities of the plurality of magnets face each other.4. The tumor surface dose enhancing radiotherapy apparatus of claim 1 , wherein the radiation beam irradiated by the radiation beam generating unit comprises a photon beam claim 1 ,wherein secondary electrons are generated by the photon beam before the body cavity in the body, andwherein the magnetic field generating unit forms ...

METHOD FOR PRODUCING LONG-FIBER COMPOSITE

The present invention pertains to a method for producing a long-fiber composite in which a fiber bundle is impregnated with a non-Newtonian resin. More specifically, the present invention pertains to a method for producing a thermoplastic long-fiber composite, wherein the efficiency of a non-Newtonian resin impregnation process is improved using Equation 1 representing the correlation between the penetration pressure, effective viscosity, transverse permeability, and average penetration velocity of the non-Newtonian resin, and the thickness of the fiber bundle. 2. The method of claim 1 , wherein the fiber bundle has porosity claim 1 , and the impregnation step comprises a porosity control step of controlling the porosity of the fiber bundle so that the penetration time required for the resin to fill the internal voids of the fiber bundle is a preset time or less.3. The method of claim 2 , wherein the porosity control step comprises a step of controlling a distance between the respective fiber units included in the fiber bundle.4. The method of claim 3 , wherein the step of controlling the distance between the respective fiber units included in the fiber bundle is performed by a method of applying a force in a direction perpendicular to the direction of applying a tension to the fiber bundle.5. The method of claim 3 , wherein the step of controlling the distance between the respective fiber units included in the fiber bundle is performed by a method of controlling the amount of the resin that penetrates into the fiber bundle.6. The method of claim 1 , wherein the roller includes a first roller and a second roller which are spaced apart from each other.7. The method of claim 6 , wherein the fiber bundle is partially impregnated by controlling the amount of the resin penetrated by the first roller.8. The method of claim 6 , wherein the impregnation step is passing the resin supplied into the container by a preset pressure through between the first roller and the second ...

Method for processing unmatched low-dose x-ray computed tomography image using neural network and apparatus therefor

A method for processing an unmatched low-dose X-ray computed tomography (CT) image using a neural network and an apparatus therefor are provided. The method includes receiving a low-dose X-ray CT image and removing noise from the low-dose X-ray CT image using a unsupervised learning based neural network learned using unmatched data to reconstruct a routine-dose X-ray CT image corresponding to the low-dose X-ray CT image.

MUSCLE RETRACTOR FOR SPINE SURGERY

Provided is a muscle retractor for spine surgery including: first and second retractors having blades configured to support a spine and muscles, and insertion blocks extending from the blades and having facing open surfaces; an expander having expansion arms slidably inserted into the insertion blocks of the first and second retractors, a gear rack movably installed at both of the expansion arms and having a gear section formed at one surface thereof, and a ratchet installed at the expansion arm moving along the gear rack and locked to or released from the gear section of the gear rack; a slider accessibly inserted into the blade of the first retractor or the second retractor in a projected state; and an auxiliary plate pivotally installed at a lower portion of the blade of the first retractor of the first and second retractors supporting the muscles. 1. A muscle retractor for spine surgery for retracting muscles from a spine , comprising:first and second retractors having blades configured to support a spine and muscles, and insertion blocks extending from the blades and having facing open surfaces;an expander having expansion arms slidably inserted into the insertion blocks of the first and second retractors to expand the first and second retractors, a gear rack movably installed at both of the expansion arms and having a gear section formed at one surface thereof, and a ratchet installed at the expansion arm moving along the gear rack and locked to or released from the gear section of the gear rack;a slider accessibly inserted into the blade of the first retractor or the second retractor in a projected state and configured to restrict or release the corresponding retractor according to access thereof; andan auxiliary plate pivotally installed at a lower portion of the blade of the first retractor of the first and second retractors supporting the muscles, and pivoted according to insertion of the expansion arm of the expander into the insertion block of the first ...

DRUG-BOUND COMPOUND AND USE THEREOF

The present invention relates to a CPT-bound compound or a pharmaceutically acceptable salt thereof, the CPT-bound compound being obtained by binding CPT (or a CPT derivative) and guanidine to a reduced monosaccharide. The CPT-bound compound enhances solubility and cell permeability of the CPT drug, which makes it possible to effectively deliver CPT to target cells. Therefore, a pharmaceutical composition comprising, as an active ingredient, the CPT-bound compound or a pharmaceutically acceptable salt thereof is expected to be able to effectively treat cancer, in particular, colorectal cancer, even with a low dose of CPT. 1. A CPT-bound compound or a pharmaceutically acceptable salt thereof , the CPT-bound compound being obtained by binding camptothecin (CPT) or a CPT derivative , and guanidine to a reduced monosaccharide.2. The CPT-bound compound or a pharmaceutically acceptable salt thereof of claim 1 , wherein the monosaccharide is any one selected from the group consisting of glucose claim 1 , sorbitol claim 1 , fructose claim 1 , mannose claim 1 , galactose claim 1 , and ribose.3. The CPT-bound compound or a pharmaceutically acceptable salt thereof of claim 1 , wherein the CPT derivative is one or more selected from the group consisting of topotecan claim 1 , irinotecan claim 1 , silatecan claim 1 , cositecan claim 1 , exatecan claim 1 , lutotecan claim 1 , gimatecan claim 1 , belotecan claim 1 , and rubitecan.4. The CPT-bound compound or a pharmaceutically acceptable salt thereof of claim 1 , wherein the CPT or CPT derivative is bound via a linker.5. The CPT-bound compound or a pharmaceutically acceptable salt thereof of claim 1 , wherein the guanidine is bound via a linker.7. The CPT-bound compound or a pharmaceutically acceptable salt thereof of claim 1 , wherein the CPT-bound compound is 1-O-[20-O-(N-succinyl-6-aminohexanoyl)camptothecin]-2 claim 1 ,3 claim 1 ,4 claim 1 ,5-tetra-O-(N-{bis-[3-(N′ claim 1 ,N″-bis-(tert-butoxycarbonyl) -guanidino)-propyl]}-6- ...

Method for quantifying medical image

A method of quantifying a medical image is disclosed herein. The method of quantifying a medical image includes acquiring regions of interest based on a medical image; filtering the sizes of the acquired regions of interest using length scale analysis; classifying the regions of interest whose sizes have been filtered, according to the sizes of the regions of interest; and visualizing the regions of interest whose sizes have been filtered, so that the regions of interest whose sizes have been filtered are distinguished from each other in the medical image according to the sizes of the regions of interest.

ELECTROMAGNETIC FORCE DRIVING DEVICE

An electromagnetic force driving device having reduced size and weight, and easily changeable electromagnetic characteristics and holding force, is provided. The device includes: a first housing; a second housing installed under the first housing; a partitioning wall partitioning the first and second housings; a first mover installed on a top of the first housing; a coil unit installed at a lower portion of the second housing to be movable according to a direction of current supplied; a second mover including one end combined with the coil unit, and another end passing through the partitioning wall and connected to the first mover to operate the first mover according to a movement of the coil unit; an upper magnet installed in the first housing to maintain a predetermined position of the first mover; and a lower magnet arranged in the second housing to form a magnetic field at the coil unit. 1. An electromagnetic force driving device comprising:a housing including a first housing in which a first mover is installed, a second housing in which a coil unit is installed, a third housing installed on a bottom surface of the second housing, and a fourth housing for partitioning the first housing and the second housings;a first mover installed on a top of the first housing to be movable in a vertical direction;a coil unit installed in parallel to the second housing to move either upwards or downwards by a repulsive force according to a direction of current supplied in a forward direction or a reverse direction;a second mover, one end of which is combined with the coil unit, and the other end of which passes through the fourth housing to be connected to the first mover, to operate the first mover according to a movement of the coil unit;an upper magnet installed in the first housing to be tightly attached to the first mover to provide a magnetic force for the first mover to maintain either a top dead point or a bottom dead point; anda lower magnet installed in the second ...

Composition and method for improving sensitivity and specificity of detection of nucleic acids using dcas9 protein and grna binding to target nucleic acid sequence

A composition and a method for improving sensitivity and specificity of detection of nucleic acids, use dCas9 and gRNA, which binds to a target nucleic acid sequence, in amplification of nucleic acids including DNAs, RNAs, and the like increases efficiency in amplification of nucleic acids and thereby can ultimately improve sensitivity and specificity of a target diagnosis on the basis of a functional difference between Cas9 and dCas9.

MARKER COMPOSITION COMPRISING S1P LIPID FOR PREDICTING RISK OF OSTEOPOROTIC FRACTURE AND OSTEOPOROSIS

Disclosed herein is a marker composition that includes sphingosine 1-phosphate (S1P) lipid and that may be used to predict the risk of fracture or osteoporosis; a kit that includes an antibody that specifically binds to the S1P lipid and that can be used to predict the risk of fracture or osteoporosis; and a method that can be used to obtain information that allows prediction of the risk of fracture or osteoporosis and includes measurements of S1P lipid concentrations by measuring the binding of a S1P-specific antibody to SIP lipid. The S1P lipid disclosed herein is highly expressed in individuals with fracture, regardless of their bone mineral density. Accordingly, it may be useful as a biomarker of the risk of fracture or osteoporosis. 1. A kit for predicting the risk of fracture or osteoporosis comprising:a sphingosine 1-phosphate (S1P) lipid-specific antibody; and an agent to measure the amount of S1P lipid-specific antibody that bind to S1P lipid.2. The kit of claim 1 , wherein the kit measure the S1P lipid concentration in blood or bone marrow fluid.3. The kit of claim 1 , wherein the antibody is a polyclonal claim 1 , monoclonal claim 1 , or recombinant antibody.4. A method for predicting the risk of fracture or osteoporosis claim 1 , the method comprising the step of:(a) measuring the Sphingosine 1-phosphate (S1P) lipid concentration in an isolated biological samples; and(b) comparing the measured S1P lipid concentration with that in a control sample.5. The method of claim 4 , wherein the biological sample is at least one of the following: tissues claim 4 , cells claim 4 , whole blood claim 4 , serum claim 4 , plasma claim 4 , saliva claim 4 , sputum claim 4 , bone marrow fluid claim 4 , and urine.6. The method of claim 4 , wherein the S1P concentration is measured by at least one of the following methods: western blot claim 4 , enzyme-linked immunosorbant assay (ELISA) claim 4 , radioimmunoassay (RIA) claim 4 , radioimmunodiffusion claim 4 , Ouchterlony ...

VASCULAR ANASTOMOSIS DEVICE USING A SELF-EXPANDABLE MATERIAL OR BODY, AND ANASTOMOSIS METHOD FOR BLOOD VESSELS USING SAME

The present invention relates to an anastomosis device for blood vessels using a self-expandable material or body, and to an anastomosis method for blood vessels using same, and more particularly, to an anastomosis device for blood vessels using a self-expandable material or body, which is self-expandable in response to external stimulation and which is removable after a procedure, and to an anastomosis method for blood vessels using same. 1. A vascular anastomosis device , comprisinga cylindrical body having a diameter of 0.5 to 5 mm and a length of 10 to 60 mm,wherein the body comprises a self-expandable material.2. The device of claim 1 ,wherein the device is disposed between both ends of a cut blood vessel so as to be located at a lumen of the blood vessel, is radially self-expanded by an expanding agent applied from the outside to fix the blood vessel, and is removable by treating a solvent capable of dissolving the device after the ends of the blood vessel are stitched together.3. The device of claim 2 ,wherein the stitching of the blood vessel performed before the device is removed is performed across a half to an entire end of the blood vessel.4. The device of claim 1 ,wherein the self-expandable material comprises starch.5. The device of claim 2 ,wherein the expanding agent comprises saline.6. The device of claim 2 ,wherein the solvent capable of dissolving the device comprises saline.7. A vascular anastomosis device claim 2 , comprising:a self-expandable wire having a diameter of 0.5 to 5 mm and a length of 10 to 60 mm; anda thread connected to the self-expandable wire.8. The device of claim 7 ,wherein the self-expandable wire is disposed between both ends of a cut blood vessel so as to be located at a lumen of the blood vessel, is radially extended to fix the blood vessel, and is removable by pulling the thread connected to the wire from the outside after the ends of the blood vessel are stitched together.9. The device of claim 8 ,wherein the stitching of ...

Breast cancer diagnosis device

The present invention relates to a breast cancer diagnosis device. More particularly, the present invention relates to a breast cancer diagnosis device for early detection of the presence or absence of breast cancer lesions inside the breast of a diagnosis subject. The breast cancer diagnosis device includes: an X-ray diagnosis unit generating an X-ray image of a diagnosis subject; an optical diagnosis unit generating an optical transmission image of the diagnosis subject; and a transfer unit which is coupled to the X-ray diagnosis unit and the optical diagnosis unit to transfer all or part of the X-ray diagnosis unit and the optical diagnosis unit, and sequentially transfer all or part of the X-ray diagnosis unit or the optical diagnosis unit toward the diagnosis subject.

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE

The present invention relates to an ibuprofen conjugate in which ibuprofen (S-(+)-ibuprofen) is covalently linked to a guanidine-terminal-group-bound sugar alcohol derivative and to a pharmaceutical composition containing the same. The ibuprofen conjugate in which ibuprofen is covalently linked to a guanidine-terminal-group-bound sugar alcohol derivative can more effectively penetrate into the brain by passing through the blood-brain barrier (BBB), thus enabling efficient drug delivery to the brain, whereby administration of the ibuprofen conjugate in an optimal dose can minimize side effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and can prevent or treat degenerative brain disease. 2. The pharmaceutical composition of claim 1 , wherein all of Rs are represented by Chemical Formula 3.3. The pharmaceutical composition of claim 1 , wherein X is any one selected from the group consisting of sorbitol claim 1 , mannitol claim 1 , galactitol claim 1 , fucitol claim 1 , iditol claim 1 , and inositol.4. The pharmaceutical composition of claim 3 , wherein X is sorbitol or mannitol.5. The pharmaceutical composition of claim 1 , wherein the brain disease is any one selected from the group consisting of stroke claim 1 , palsy claim 1 , dementia claim 1 , Alzheimer's disease claim 1 , Parkinson's disease claim 1 , Lou Gehrig's disease claim 1 , Huntington's disease claim 1 , Pick's disease claim 1 , Creutzfeldt-Jakob disease claim 1 , thrombosis claim 1 , embolism claim 1 , transient ischemic attack claim 1 , lacune claim 1 , multiple sclerosis claim 1 , proximal lateral sclerosis claim 1 , palsy claim 1 , stroke claim 1 , mild cognitive impairment claim 1 , cerebral hemorrhage claim 1 , cerebral infarction claim 1 , head trauma claim 1 , cerebral circulation metabolic disorder claim 1 , and brain coma.7. The compound of claim 6 , wherein all of Rs are represented by Chemical Formula 3.8. The compound of claim 6 , wherein X is any one selected from the group consisting ...

METHOD FOR VERIFYING DRONE INCLUDED IN INDUSTRIAL INTERNET OF THINGS SYSTEM, BY USING PETRI-NET MODELING

A method for verifying a drone included in an industrial Internet of Things (IIoT) system, using a petri-net modeling is disclosed. In an embodiment, the method includes a step of modeling the IIoT system as a hierarchical petri-net (modeling step); and a step of verifying whether the drone has security vulnerability on the basis of the hierarchical petri-net model (verification step), wherein the verification step can determine that a drone has security vulnerability when at least one of a plurality of determination factors provided as places to the hierarchical petri-net model determines that the drone is operating abnormally. 1. A method of verifying a drone included in an industrial Internet of things (IIoT) system using petri net modeling , the method comprising:a modeling step of modeling the industrial Internet of things system into a hierarchical type petri net; anda verification step of verifying whether security vulnerability is present in the drone based on a hierarchical type petri net model,wherein the verification step comprises determining that the security vulnerability is present in the drone when at least one of a plurality of determination factors included as places in the hierarchical type petri net model determines an operation of the drone to be abnormal.2. The method of claim 1 , wherein the plurality of determination factors comprises:a first place for determining whether communication or an operation of the drone is hindered from an outside;a second place for determining whether a waypoint on a moving path in which the drone has been set is altered;a third place for determining whether a plurality of the drones forms enforced clustering that has not been set;a fourth place for determining whether the drone has been captured;a fifth place for determining whether access control over the drone is possible; anda sixth place for determining whether the drone has been authorized by the industrial Internet of things system.3. The method of claim 2 ...

PRIVACY MASKING METHOD USING FORMAT-PRESERVING ENCRYPTION IN IMAGE SECURITY SYSTEM AND RECORDING MEDIUM FOR PERFORMING SAME

The present invention discloses a privacy masking method using format-preserving encryption in an image security system, and a recording medium for performing the method. In a privacy masking method using format-preserving encryption in an image security system according to an aspect of the present invention, an image corresponding to a privacy region is encrypted using format-preserving encryption, so that it is possible to prevent waste of additional storage space required for encryption and to solve a problem of exposure of personal information. 1. A privacy masking method using format-preserving encryption in an image security system , the method comprising:receiving, from an image surveillance system, an image obtained at at least one place;identifying whether information related to privacy is present within the received image;extracting, when the information related to privacy is present as a result of the identification, a privacy region from the received image;calculating a size of an image with respect to the extracted privacy region;generating a block size for generating ciphertext in such a manner as to be equal to the calculated image size;generating the ciphertext by using format-preserving encryption according to the generated block size, and generating a privacy masking image by using the generated ciphertext; andinserting the encrypted privacy region image to the region related to privacy within the image received from the image surveillance system.2. The privacy masking method of claim 1 , wherein the generating of the block size for generating the ciphertext in such a manner as to be equal to the calculated image size includes:a primary block size generation step in which the block size in a fixed size is generated; anda secondary block size generation step in which the block size in a variable size is generated by subtracting the generated block size in the fixed size from the calculated image size.3. The privacy masking method of claim 2 , ...

Nucleic acid extraction method using solid subject

The present invention relates to a nucleic acids extraction method using a solid subject, and it can isolate nucleic acids with large amounts and high purity at a low cost and simpler than conventional methods of extracting nucleic acids by forming a complex of a nucleic acids sample and an imidoesters compound in the subject, and particularly, the thin film device used for extracting nucleic acids has improved hydrophilicity compared to the conventional silicon substrate, so that nucleic acids can be extracted more efficiently.

BRAIN DISEASE DIAGNOSIS SERVICE APPARATUS AND BRAIN DISEASE DIAGNOSIS SERVICE METHOD

The present disclosure relates to a brain disease diagnosis service apparatus including at least: a receiving unit for receiving an image of a subject to be diagnosed; a preprocessing unit for estimating a transformation matrix in order to align a predetermined standard image with the image received by the receiving unit, and for applying the estimated transformation matrix to a predetermined standard brain region map, thereby generating an individual brain region map for the subject to be diagnosed; a feature point extracting unit for calculating a ratio occupied by brain lesions for each brain region in the individual brain region map, generated by the preprocessing unit, of the subject to be diagnosed, thereby extracting feature points; and a disability type determining unit for determining a disability type on the basis of the ratio of the brain lesions, calculated by the feature point extracting unit, for each brain region. 1. An apparatus for servicing a brain disease diagnosis based on an image obtained from a magnetic resonance imaging (MRI) apparatus , the apparatus comprising:a receiving unit configured to receive an image of a diagnostic subject obtained from the MRI apparatus;a preprocessing unit configured to estimate a transformation matrix for matching a preset standard image to the image received from the receiving unit and apply the transformation matrix to a preset standard brain region map such that an individual brain region map of the diagnostic subject is generated;a feature extracting unit configured to calculate an occupancy ratio of a brain lesion of each brain region in the individual brain region map of the diagnostic subject generated from the preprocessing unit to extract a feature; anda disability type determining unit configured to determine a disability type based on the occupancy ratio of the brain lesion of each brain region calculated by the feature extracting unit.2. The apparatus of claim 1 , wherein the image of the diagnostic ...

METHOD FOR TESTING NK CELL ACTIVITY USING SYNERGISTIC ACTIVITY OF RECEPTOR, AND METHOD FOR DIAGNOSING DISEASE ASSOCIATED WITH NK CELL ACTIVITY USING SAME

Provided are a method of testing NK cell activity, including: specifically stimulating at least two distinguishable factors on NK cells in a sample; measuring a synergistic activation level of the NK cells; and comparing the synergistic activation level of the NK cells with that of normal NK cells, and a composition for testing NK cell activity. In addition, the present disclosure relates to a kit for diagnosing an NK cell synergistic activity-associated disease, the kit including the composition. 1. A method of testing NK cell activity , the method comprising:specifically stimulating at least two distinguishable factors on NK cells in a sample;measuring a synergistic activation level of the NK cells, induced by stimulation of the at least two factors; andcomparing the synergistic activation level of the NK cells with that of normal NK cells.21. The method of clam , further comprising isolating target NK cells from the sample.3. The method of claim 1 , wherein the factors are present on surfaces of the NK cells or in the NK cells.4. The method of claim 3 , wherein the factors are selected from NKG2D claim 3 , 2B4 (CD244) claim 3 , DNAM-1 (CD226) claim 3 , CD2 claim 3 , CD16 claim 3 , NKp30 claim 3 , NKp44 claim 3 , NKp46 claim 3 , and NKp80.5. The method of claim 1 , wherein the stimulating is performed on the factors simultaneously or sequentially.6. The method of claim 1 , wherein the stimulating is performed by at least one selected from an antibody or fragment thereof specific to each or all of the factors claim 1 , a target cell or polypeptide that induces specific activity claim 1 , a compound that specifically induces activity claim 1 , and a reversible or irreversible agonist.7. The method of claim 6 , wherein the target cell that induces specific activity in the factors is coated with at least one selected from an antibody against the at least two distinguishable factors on NK cells claim 6 , a fragment thereof claim 6 , and a combination thereof.8. The ...

Server for building big data database based on quantification and analysis of medical images and server-based medical image analysis method

Disclosed are a server and a server-based medical image analysis method. A medical image analysis server according to an embodiment of the present invention includes at least one processor. The at least one processor is configured to: automatically transmit a retrieval query to a first database in which medical images are stored; control a receiving interface so that the receiving interface receives a first medical image satisfying the retrieval query from the first database; perform image processing on the first medical image and extract at least one first region of interest from the first medical image; quantify a first feature extracted for the first medical image and the at least one first region of interest; and store the first feature in a second database in association with the first medical image and the retrieve condition.

食道听诊器

提供一种食道听诊器。所述食道听诊器包括：套件；管，一侧端部布置于所述套件的内部并延伸到另一侧；安装部件，安装于所述管的另一侧端部；以及麦克风，布置于所述安装部件的内部，其中，所述管包括：至少一个孔，使通过套件的声波被提供到所述管内，所述麦克风吸收心音并将其转换为心意电信号，并且与外部装置电连接而将所述心音电信号传输到所述外部装置。

Organic light emitting device

An organic light emitting device is provided. The organic light emitting device includes a lower electrode disposed on a substrate, a first organic layer disposed on the lower electrode and configured to be used as a hole transport layer and an emitting layer, a second organic layer disposed on the first organic layer and configured to be used as a hole blocking layer and an electron transport layer, and an upper electrode disposed on the second organic layer. With manufacturing of an organic light emitting device having only two organic layers (first and second organic layers) between the upper electrode and the lower electrode, the structure of the organic light emitting device is simplified. Thus, the driving voltage of the organic light emitting device is reduced, and luminous efficiency is improved. Moreover, the deposition process is simplified to shorten the processing time by forming only two organic layers.

Use DTBP concentrate microbial or the method for extracting nucleic acid

本发明涉及使用DTBP的用于浓缩微生物和提取核酸的方法。已经开发了能够使用DTBP浓缩微生物的技术，并且还已经开发了能够从浓缩的微生物中直接提取核酸的方法。由于浓缩微生物和提取核酸的技术可以在一个管或芯片中实现，因此期望显著减少来自外部的污染、成本、时间、复杂性等。

Multi-wavelength endoscopic system and image processing method using same

There is disclosed a multi-wavelength endoscopic system for imaging an observation site labeled with a plurality of fluorescent materials having different colors. The system includes an imaging unit configured to acquire image data by polarizing incident light reflected from the observation site in a first direction and a second direction perpendicular to the first direction, dividing a spectrum region of the incident light polarized in the first direction and the second direction into a plurality of spectrum channels and measuring the intensity of light for each of the spectrum channel. The system further includes a computing unit configured to store a single fluorescence spectrum extracted from sample image data obtained by single-treating the observation site with each of the fluorescent materials and configured to separate and output the image data obtained in the imaging unit using the single fluorescence spectrum so that each of the fluorescent materials is displayed separately.

Radioisotope-labeled complexes of glucose derivatives and kits for the preparation thereof

The present invention relates to a complex comprising one or more radioisotopes selected from the group consisting of ?99mTc, 188Re and 186¿Re chelated to a glucose derivative having an intramolecular nitrogen or sulfur atom, which is very useful as tumor diagnostic agents. It also relates to a kit for the preparation thereof comprising the glucose derivative and a reducing agent.

Method for testing nk cell activity using synergistic activity of receptor, and method for diagnosing disease associated with nk cell activity using same

Provided are a method of testing NK cell activity, including: specifically stimulating at least two distinguishable factors on NK cells in a sample; measuring a synergistic activation level of the NK cells; and comparing the synergistic activation level of the NK cells with that of normal NK cells, and a composition for testing NK cell activity. In addition, the present disclosure relates to a kit for diagnosing an NK cell synergistic activity-associated disease, the kit including the composition.

Device and method for detecting guidewire

An electronic device includes a processor configured to generate a position movement prediction field indicating prediction of a potential positional change of a branch path by a patient's biological activity for one or more branch paths based on a blood vessel image of a reference frame, correct guidewire information extracted from a blood vessel image of a target frame with respect to a catheter position of the reference frame, and select a branch path to dispose the guidewire information, among one or more branch paths of a blood vessel region based on the position movement prediction field and the corrected guidewire information; and a display configured to visualize the guidewire information on the selected branch path.

Endoscopic procedure simulator module and endoscopic procedure simulator using same

The inventive concept relates to an endoscopic procedure simulator module and an endoscopic procedure simulator using the same. The endoscopic procedure simulator module according to the inventive concept includes a lesion indicating part having a discharge hole formed therein, through which a fluid is discharged to present a bleeding state, a module body to which the lesion indicating part is coupled, the module body having a fluid channel and a spacing space formed therein, in which the fluid to be discharged through the discharge hole flows through the fluid channel and the spacing space is separated from the fluid channel, and a diaphragm provided in the spacing space of the module body so as to be expandable, in which the diaphragm is expanded by a separate fluid injected into the spacing space and closes the discharge hole of the lesion indicating part.

Composition for preventing or treating obesity containing alpha-lipoic acid and N-acetylcysteine as active ingredients

The present invention provides a composition containing a-lipoic acid and N acetylcysteine as active ingredients. The mixed composition of a-lipoic acid and N-acetylcysteine of the present invention can reduce a risk of side effects due to 5 drugs with synergetic effects due to merge administration of two drugs, and can be usefully used for preventing or treating obesity with excellent effects of inhibiting a weight gain compared to each single composition containing a-lipoic acid or N acetylcysteine.

Sensitivity prediction new biomarkers relevant with EGF-R ELISA target preparation and application thereof

本发明涉及用于预测与表皮生长因子受体‑靶制剂有关的感受性的新型生物标志物及其的用途，更详细地提供如下：与表皮生长因子受体(EGFR，Epidermal Growth Factor Receptor)‑靶制剂有关的感受性预测用生物标志物，包含RON(Recepteur d’Origine Nantais)基因；与表皮生长因子受体‑靶制剂有关的感受性预测用组合物，包含用于测定上述生物标志物的基因表达水平或上述基因的蛋白质的表达或活性水平的制剂；与表皮生长因子受体‑靶制剂有关的感受性增进用组合物，包含如下的抑制剂作为有效成分：上述抑制剂是指用于抑制上述基因的表达或者抑制上述基因的蛋白质的表达或活性的抑制剂；包含上述组合物的与表皮生长因子受体‑靶制剂有关的感受性预测用试剂盒；以及与表皮生长因子受体‑靶制剂有关的感受性预测方法。根据本发明，本发明与在大肠癌中的表皮生长因子受体‑靶制剂有关的感受性预测效果优秀，因此本发明能够有用地利用于大肠癌治疗。

Closed reduction device for fracture

The present disclosure relates to an apparatus for closed reduction of a bone fracture. The apparatus includes a pulling adaptor including a handle configured to be gripped by an operator, an insertion rod that is extended from the handle in a longitudinal direction of the handle, and configured to be inserted into the bone fracture which is depressed in at least one area thereof, and a pulling lug that is bent and extended from a free end of the insertion rod such that the pulling lug is perpendicular to the insertion rod or such that the pulling lug is inclined with respect to the insertion rod, that pulling lug being configured to be inserted into the fracture, which is depressed, in order to pull the bone fracture.

Method for testing nk cell activity using synergistic activity of receptor, and method for diagnosing disease associated with nk cell activity using same

Paper-based, nucleic acid-detecting kit and method for analysis of pcr amplicon

The present invention provides a paper-based, nucleic acid-detecting sensor capable of easily and simply detecting the presence of a target nucleic acid from a PCR amplicon. In addition, the present invention provides a paper-based, nucleic acid-detecting kit capable of easily and simply detecting the presence of a target nucleic acid from a PCR amplicon and a nucleic acid detecting method using same. The present invention can easily and simply determine the presence or absence of a target nucleic acid in a PCR amplicon by utilizing the function in which the target nucleic acid is associated with nanoparticles to form a composite and when loaded into the sensor, the composite is separated and moves according to the structure of the sensor and is finally visualized on the sensor.

No details

Method for preparation of organofluoro compounds in alcohol solvents

The present invention relates to a method for preparation of organofluoro compounds containing radioactive isotope fluorine-18. More particularly, the present invention relates to a method for preparation of organofluoro compound [ 18 F]florbetaben or [ 18 F]AV-45 having <Chemistry Formula 11> and <Chemistry Formula 12>, respectively, by reacting fluorine salt containing radioactive isotope fluorine-18 with alkyl halide or alkyl sulfonate in the presence of alcohol of Chemistry Formula 1 as a solvent to obtain high yield of organofluoro compound. Synthesis reaction according to the present invention may be carried out under mild condition to give high yield of the organofluoro compounds and the reaction time is decreased, and thereby is suitable for the mass production of the organofluoro compounds.

Composition for preventing or treating valve calcification, containing dpp-4 inhibitor

The present invention relates to a composition for preventing or treating valve calcification, containing a dipeptidyl peptidase-4 (DPP-4) inhibitor. The DPP-4 inhibitor according to the present invention may include all of what can inhibit the expression of DPP-4 nucleotides or the activity of DPP-4 proteins, wherein: DPP-4 antibodies, sitagliptin, vildagliptin, saxagliptin, linagliptin, dutogliptin, gemigliptin, alogliptin, Anagliptin, evogliptin, Berberine, Diprotin, or Lupeol; DPP-4 mRNA anti-sense nucleotides, aptamers, small interfering RNA (siRNA), short hairpin RNA (shRNA), and microRNA (miRNA), or RNA interference (RNAi); or the like can be used.

Customized surgical guide and customized surgical guide generating method and generating program

The present invention relates to a customized surgical guide device and a customized surgical guide generating method and program. A customized surgical guide generating method according to another embodiment of the present invention comprises the steps of: acquiring body surface data and treatment area data from medical image data by a computer (S100); a first shape data generating step of generating first shape data on the basis of the body surface data, wherein the first shape data is data which corresponds to the shape of the body part cover (S300); a target point setting step of setting one or more target points, wherein the target point is a point which corresponds to the inside or the surface of an area to be treated (S500); setting individual first points on the body surface accessible to the target point with a medical tool (S700); setting a guide tube length on the basis of a distance from the first point to the target point (S900); and generating final shape data in which one or more guide tubes are combined to the first shape data by applying the guide tube length to the first point (S1100).

Biomarker composition comprising lrp-1 as active ingredient, for diagnosis of radiation-resistant cancer or prediction of radiation therapy prognosis

The guide tool and its manufacturing method for corniculi maxillaris cutting operation based on threedimensional model

本发明涉及用于下颚角切割手术的引导器具及其制造方法。更具体地，本发明涉及一种引导器具，其配置成保护下颚骨周边的神经、软组织和下颚骨的骨骼，配置成被有效地固定至手术对象的下颚骨的外骨骼上，并且配置成引导切割器具的移动路径。根据本发明实施方式的用于下颚切割手术的引导结构物具有内壁，该内壁的轮廓准确地遵循手术对象的手术前下颚的三维模型的外表面的形状。作为用于下颚切割手术的引导结构物的一部分，与手术对象的下颚的外侧接触的该部分的外围的边界面沿着预先设定的模拟上的切割面形成。

Composition for improving, preventing or treating skin disease comprising induced pluripotency stem cell-derived mesenchymal stem cells pretreated with interferon gamma and exosomes derived therefrom

Microbial concentration method using diatomite and nucleic acid extraction method

The present invention relates to a method of concentrating microorganisms and a method of extracting nucleic acids using diatomaceous earth and developed a technology capable of concentrating microorganisms about 4-8 times using the modified diatomaceous earth and directly extracting nucleic acids from the concentrated microorganism using dimethyl adipimidate (DMA). It is expected to significantly reduce external contamination, cost, time and complexity by enabling microbial concentration and nucleic acid extraction techniques in one tube.

Method for distinguishing pulmonary artery and pulmonary vein, and method for quantifying blood vessels using same

A method for distinguishing between pulmonary arteries and pulmonary veins and a method for quantifying blood vessels are disclosed. The method for distinguishing between pulmonary arteries and pulmonary veins includes: forming a set of pulmonary vessels for points corresponding to pulmonary vessels, wherein each of the points of the set of pulmonary vessels has weight information; forming a tree from the points of the set of pulmonary vessels by using the weight information; and distinguishing between the pulmonary arteries and the pulmonary veins by separating the tree into a plurality of regions. The method for quantifying blood vessels includes: extracting blood vessels as a three-dimensional set of voxels based on medical images of an organ; finding the voxels of blood vessels included in a region of interest of the organ; and quantifying length information of the blood vessels by using the found voxels.

Radioisotope-labeled complexes of glucose derivatives and kits for the preparation thereof

The present invention relates to a complex comprising one or more radioisotopes selected from the group consisting of ?99mTc, 188Re and 186¿Re chelated to a glucose derivative having an intramolecular nitrogen or sulfur atom, which is very useful as tumor diagnostic agents. It also relates to a kit for the preparation thereof comprising the glucose derivative and a reducing agent.

COMPOSITION FOR THE PREVENTION OR TREATMENT OF OBESITY CONTAINING ALPHA-LIPOIC ACID AND N-ACETYLCYSTEINE AS ACTIVE INGREDIENTS

a presente invenção proporciona uma composição contendo ácido alfa-lipóico e n-acetilcisteína como ingredientes ativos. a composição mista de ácido alfa-lipóico e n-acetilcisteína da presente invenção pode reduzir o risco de efeitos secundários devido a fármacos com efeitos sinergéticos devido à administração em série de dois fármacos e pode ser útil para prevenir ou tratar a obesidade com excelentes efeitos de inibição de um ganho de peso em comparação com cada composição única contendo ácido alfa-lipóico ou n-acetilcisteína the present invention provides a composition containing alpha-lipoic acid and n-acetylcysteine as active ingredients. the mixed composition of alpha-lipoic acid and n-acetylcysteine of the present invention can reduce the risk of side effects due to drugs with synergistic effects due to the serial administration of two drugs and can be useful to prevent or treat obesity with excellent effects of inhibition of weight gain compared to each single composition containing alpha-lipoic acid or n-acetylcysteine

Method for preparation of F-18 containing organofluoro compounds in alcohol solvents

The present invention relates to a method for preparation of organofluoro compounds containing radioactive isotope fluorine-18. More particularly, the present invention relates to a method for preparation of primary or secondary organofluoro compound by reacting fluorine salt containing radioactive isotope fluorine-18 with primary or secondary alkyl halide or primary or secondary alkyl sulfonate in the presence of alcohol of Chemical Formula 1 as a solvent to obtain high yield of organofluoro compound. Synthesis reaction according to the present invention may be carried out under mild condition to give high yield of the organofluoro compounds and the reaction time is decreased, and thereby is suitable for the mass production of the organofluoro compounds.

Customized surgical guide and customized surgical guide generating method and generating program

The present invention relates to a customized surgical guide device and a customized surgical guide generating method and program. A customized surgical guide generating method according to another embodiment of the present invention comprises the steps of: acquiring body surface data and treatment area data from medical image data by a computer (S100); a first shape data generating step of generating first shape data on the basis of the body surface data, wherein the first shape data is data which corresponds to the shape of the body part cover (S300); a target point setting step of setting one or more target points, wherein the target point is a point which corresponds to the inside or the surface of an area to be treated (S500); setting individual first points on the body surface accessible to the target point with a medical tool (S700); setting a guide tube length on the basis of a distance from the first point to the target point (S900); and generating final shape data in which one or more guide tubes are combined to the first shape data by applying the guide tube length to the first point (S1100).

Customized surgical guide and customized surgical guide generating method and generating program

CUSTOMIZED SURGICAL GUIDE AND CUSTOMIZED SURGICAL GUIDE GENERATING METHOD AND GENERATING PROGRAM CROSS-REFERENCE TO RELATED APPLICATIONS 5 [0001] The present application is a divisional application of Australian Patent 2017361460, which is a continuation of International Patent Application No. PCT/KR2017/012906, filed November 15, 2017, which is based upon and claims the benefit of priority to Korean Patent Application No. 10-2016-0152885, filed on November 16, 2016. The disclosures of the above-listed applications are hereby 10 incorporated by reference herein in their entirety. BACKGROUND [0002] Embodiments of the inventive concept described herein relate to a customized surgical guide, and a customized surgical guide producing method, and a 15 producing program, and more particularly, to a customized surgical guide, a customized surgical guide producing method, and a producing program by which surgery is performed in accordance with a state of a treatment target region of a specific patient during the specific patient's surgery. [0003] In surgery, medical staffs measure a region to be subjected to surgery 20 based on medical images. In this process, the region measurement is dependent on the surgeon's eye-based measurement and experience. Thus, it may happen that a region to be removed is not completely removed. Further, a region to be removed is not accurately measured such that a large region than the region to be removed is cut off. 25 [0004] Further, a removal area on a skin surface is marked before surgery is 1 performed. However, when the surgery starts and the body portion is excised, a marker on the surface of the skin may not match an inner portion to be removed, such that an accuracy at which the scope of surgery within the body portion is determined is lowered. In order to mark a certain point inside the body, an ultrasonic 5 or mammography guide H-wire is inserted to remove a corresponding body portion. This may have marking inaccuracy. ...

S1pr4-targeting composition for preventing or treating non-alcoholic steatohepatitis

The present invention relates to a S1PR4-targeting composition for preventing or treating non-alcoholic steatohepatitis and, more particularly, to a pharmaceutical composition and a health functional food composition, both comprising a sphingolipid compound which serves as a functional inhibitor against S1PR4, showing prophylaxis and therapy of non-alcoholic steatohepatitis. The sphingolipid compound of the present invention is expected to be applied as a leading material effective for the prevention or treatment of non-alcoholic steatohepatitis (NASH) as it has the effect of reducing the infiltration of inflammatory cells into hepatic tissues and suppressing fibrosis and decreases a level of liver injury (ALT), inflammation in hepatic tissues, the expression of a fibrosis-related gene.

Thrombus imaging radiopharmaceutical and composition

The present invention relates to a thrombus imaging radiopharmaceutical for radioisotope labeling. The radiopharmaceutical of the present invention binds to glycoprotein Ilb/IIIa with high affinity, enables thrombus imaging through quick reduction of background radioactivity, and can be simply synthesized at high yield by coupling a chelator to a metallic radioisotope. In addition, the radiopharmaceutical can be easily prepared in hospitals using a quick and convenient preparation method, which has been a challenge for conventional radiopharmaceuticals, and thus is expected to be advantageously applied to emergency patients.

Process for the preparation of organic fluorine compounds in alcoholic solvents.

Foreliggende oppfinnelse angår en framgangsmåte for framstilling av organiske fluorholdige forbindelser som inneholder radioaktiv isotop fluor-18. Mer spesifikt angår foreliggende oppfinnelse en framgangsmåte for framstilling av en organisk fluorholdig forbindelse ved å reagere fluorsalt som inneholder en radioaktiv isotop fluor-18 med alkylhalid eller alkylsulfonat i nærvær av alkohol med kjemisk formel (I), hvor R1, R2 og R3 er hydrogen eller C1 ~ C18 alkyl-gruppe, som løsningsmiddel for å oppnå et høyt utbytte av organisk fluorholdig forbindelse. Syntesereaksjonen i samsvar med foreliggende oppfinnelse kan utføres under milde forhold for å gi et høyt utbytte av de organiske fluorholdige forbindelsene og reaksjonstiden er redusert, og den er dermed egnet for masseproduksjonen av de organiske fluorholdige forbindelsene. (I)

Utilize the detection method of the thyroid follcular carcinoma diagnosis marker of related Aminoacyl-tRNA Synthetases correlative protein expression level

本发明涉及一种用氨基酰‑tRNA合成酶相关蛋白表达水平诊断甲状腺滤泡癌的标志物检测方法，更具体地说，为了提供诊断疑似甲状腺滤泡癌患者所需的信息，包括步骤：(a)提供源自疑似甲状腺滤泡癌的被检体样本；(b)检测上述样本中氨基酰‑tRNA合成酶(aminoacyl‑tRNA synthetase,ARS)或氨基酰‑tRNA合成酶复合物‑结合多功能蛋白(aminoacyl‑tRNA synthetase complex‑interacting multifunctional protein,AIMP)的蛋白表达水平；以及(c)一种检测甲状腺滤泡癌标志物的方法，包括将上述检测的蛋白表达水平与比对组进行比较，确定蛋白表达水平变化的被检体确诊为甲状腺滤泡癌。具体而言，本发明公开的蛋白质种类可简单准确地诊断甲状腺滤泡癌，并不需通过手术提取组织，其诊断灵敏度高且特异性强。

S1PR4-targeting composition for preventing or treating non-alcoholic steatohepatitis

The present invention relates to a S1PR4-targeting composition for preventing or treating non-alcoholic steatohepatitis and, more particularly, to a pharmaceutical composition and a health functional food composition, both comprising a sphingolipid compound which serves as a functional inhibitor against S1PR4, showing prophylaxis and therapy of non-alcoholic steatohepatitis. The sphingolipid compound of the present invention is expected to be applied as a leading material effective for the prevention or treatment of non-alcoholic steatohepatitis (NASH) as it has the effect of reducing the infiltration of inflammatory cells into hepatic tissues and suppressing fibrosis and decreases a level of liver injury (ALT), inflammation in hepatic tissues, the expression of a fibrosis-related gene.

Method for culturing 3-dimensional lung cancer organoid and method for preparing patient-derived xenograft animal model using same

Method for preparing fluorine-18 eluent with adjusted ph, and method for labelling fluorine-18 using same

Hybrid stent

A hybrid stent includes multiple main cells aligned in a spiral shape and including multiple first link units which are aligned diagonally and spaced at a predetermined distance from each other and multiple second link units which connect adjacent first link units among the multiple first link units and are spaced at a predetermined distance from each other, and one or more open cells adjacent to the multiple main cells in a longitudinal direction and aligned in a spiral shape.

Method for preparation of organofluoro compounds in alcohol solvents

Composition for diagnosing follicular thyroid carcinoma using expression level of aminoacyl-trna synthetase-related protein and method for detecting diagnostic marker

Composition for preventing or treating valve calcification, containing dpp-4 inhibitor

Wound dressing material comprising fibrillated accellular dermis matrix and biodegradeable polymer, and preparation method therefor

The present invention relates to a wound dressing material comprising a fibrillated acellular dermis matrix and a biodegradable polymer aqueous solution and, more specifically, to: a wound dressing material comprising 5-20 wt % of a fibrillated acellular dermis matrix, 0.5-5 wt % of a biodegradable polymer, and 75-94.5 wt % of water; and a preparation method therefor.

Composition for preventing or treating valve calcification containing DPP-4 inhibitor

本发明涉及用于预防或治疗瓣膜钙化的组合物，其含有二肽基肽酶‑4(DPP‑4)抑制剂。本发明的DPP‑4抑制剂可包括所有可抑制DPP‑4核苷酸的表达或DPP‑4蛋白的活性的物质，其中：可使用DPP‑4抗体、西格列汀、维格列汀、沙格列汀、利格列汀、度格列汀、吉格列汀、阿格列汀、阿拉格列汀、依格列汀、小檗碱、抑二肽素或羽扇豆醇；DPP‑4mRNA反义核苷酸、适体、小干扰RNA(siRNA)、短发夹RNA(shRNA)和微小RNA(miRNA)或RNA干扰(RNAi)等。

Insertion device that can adjust the irradiation direction

Method for examining activity of NK cell utilizing receptor synergistic activity and diagnostic method using same

本发明涉及NK细胞的活性检查方法，其包括：特异性地刺激样品内的NK细胞上的可区别的2种以上的因子的步骤；测定所述NK细胞的协同活化程度的步骤；及对正常NK细胞对比所述NK细胞的协同活化程度进行比较的步骤，及NK细胞的活性检查用组合物。另外，本发明涉及与NK细胞的协同活性关联的疾病的诊断用试剂盒，其包含所述组合物。

Composition for preventing or treating obesity containing alpha-lipoic acid and N-acetylcysteine as active ingredients

The present invention provides a composition containing a-lipoic acid and N acetylcysteine as active ingredients. The mixed composition of a-lipoic acid and N-acetylcysteine of the present invention can reduce a risk of side effects due to 5 drugs with synergetic effects due to merge administration of two drugs, and can be usefully used for preventing or treating obesity with excellent effects of inhibiting a weight gain compared to each single composition containing a-lipoic acid or N acetylcysteine.

Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient

Method for preparing organic fluoride-aliphatic compound and method for purifying organic fluoride-aliphatic compound

The present invention relates to a method for preparing a radiopharmaceutical and, specifically, to a method for preparing an organic fluoride-aliphatic compound usable as a radiopharmaceutical, to a method for purifying the prepared organic fluoride-aliphatic compound, and to a method for preparing a radiopharmaceutical using a cassette comprising a backdraft preventing reaction container. According to the present invention, the organic fluoride-aliphatic compound can be prepared and purified through even a simple process at high yield, high efficiency, and high purity, and the radiopharmaceutical can be safely prepared without damage to a synthetic apparatus.

The fat prevention as active ingredient or therapeutic composition comprising alpha lipoic acid and N acetylcysteines

本发明涉及包含α‑硫辛酸及N‑乙酰半胱氨酸作为有效成分的组合物。本发明的α‑硫辛酸及N‑乙酰半胱氨酸的混合组合物借助两种药物的合并给药引起的协同效果，来减少由药物引起的副作用的危险，与包含α‑硫辛酸或N‑乙酰半胱氨酸的各个单一组合物相比，体重增加抑制效果优秀，因此可有用地利用于肥胖的预防或治疗。

Method for estimating time of occurrence of infarct on basis of brain image

Multi-wavelength endoscopic system and image processing method using same

The present invention relates to a multi-wavelength endoscope system for photographing an observation site marked with a plurality of fluorescent materials having different colors, the system comprising: a photographing unit for polarizing incident light reflected at the observation site in a first direction and a second direction perpendicular to the first direction, dividing a spectral region of the incident light polarized in the first direction and the second direction into a plurality of spectral channels, and measuring light intensity of each of the plurality of spectral channels to obtain image data; and a computing unit for storing a single fluorescence spectrum extracted from sample image data photographed by singly processing the observation site with each of the fluorescent materials, and separating and outputting the image data photographed by the photographing unit by using the single fluorescence spectrum so that only one of the plurality of fluorescent materials is displayed.

Method for preparation of organofluoro compounds in alcohol solvents

The present invention relates to a method for preparation of organofluoro compounds containing radioactive isotope fluorine- 18. More particularly, the present invention relates to a method for preparation of organofluoro compound by reacting fluorine salt containing radioactive isotope fluorine- 18 with alkyl halide or alkyl sulfonate in the presence of alcohol of Chemistry (Figure 1) as a solvent to obtain high yield of organofluoro compound. Synthesis reaction according to the present invention may be carried out under mild condition to give high yield of the organofluoro compounds and the reaction time is decreased, and thereby is suitable for the mass production of the organofluoro compounds.

Composition for preventing or treating valve calcification containing DPP-4 inhibitor

本发明涉及用于预防或治疗瓣膜钙化的组合物，其含有二肽基肽酶‑4(DPP‑4)抑制剂。本发明的DPP‑4抑制剂可包括所有可抑制DPP‑4核苷酸的表达或DPP‑4蛋白的活性的物质，其中：可使用DPP‑4抗体、西格列汀、维格列汀、沙格列汀、利格列汀、度格列汀、吉格列汀、阿格列汀、阿拉格列汀、依格列汀、小檗碱、抑二肽素或羽扇豆醇；DPP‑4mRNA反义核苷酸、适体、小干扰RNA(siRNA)、短发夹RNA(shRNA)和微小RNA(miRNA)或RNA干扰(RNAi)等。

Stent for the coil embolization of a cerebral aneurysm

Method and apparatus for predicting brain disease change through machine learning and program for the same

A method for predicting brain disease state change is disclosed. The method includes acquiring test images obtained by capturing a portion of a human brain at a time interval, performing a pre-processing procedure of converting the test images into test voxels configured to be processed for image analysis, wherein a respective test voxel of the test voxels is composed of three-dimensional voxel units, mapping first and second test voxels selected from the test voxels acquired from a patient, with each other on a three-dimensional voxel unit, wherein the first test voxel is acquired at a first time-point and the second test voxel is acquired at a second time-point, generating a voxel-based data-set based on the mapped first and second test voxels, extracting a change in the test voxels using a deep neural network, and generating a state change probability model based on the change in the test voxels.

抗c4d嵌合抗原受体调节性t细胞及其用途

抗体介导的排斥(ABMR)是成功移植(包括ABO血型不相容(ABOi)移植)的主要障碍之一。C4d沉积是ABMR的标志物，并且也见于大多数ABOi同种异体移植物组织中。本文描述了抑制ABOi同种异体移植物中的ABMR的抗C4d CAR Treg。通过将CAR逆转录病毒转导到CD62L + CD4 + CD25 + Treg中而制备的抗C4d CAR Treg以与未转导的Treg类似的程度表达Foxp3、CD25、CTLA‑4、LAP和GITR。抗C4d CAR Treg通过与C4d特异性结合而被活化，并抑制体外T细胞增殖以及未转导的Treg。此外，抗C4d CAR Treg的过继转移显著延长了小鼠ABOi心脏同种异体移植物的存活(P<0.05)。

Method and apparatus for calculating coronary artery calcium score

A method for calculating a coronary artery calcium score, the method comprising acquiring a target image for a coronary artery and myocardium before contrast enhancement, identifying the coronary artery included in the target image by using an artificial neural network, calculating a coronary artery calcium score based on the identified coronary artery, wherein the artificial neural network is trained based on a training database generated via alignment between a pre-acquired image of a coronary artery and myocardium before contrast enhancement and a pre-acquired image of a coronary artery and myocardium after contrast enhancement.

Composition for differential diagnosis of malignant peripheral nerve sheath tumor

The present invention relates to a composition for the differential diagnosis of malignant peripheral nerve sheath tumor (MPNST), a differential diagnosis kit comprising same, a method for providing information required for differential diagnosis of MPNST using same, a method for screening materials for preventing, alleviating, and treating MPNST, and the like. Using the composition capable of detecting the protein marker of the present invention has the effect of making it possible to predict and diagnose whether a malignant tumor has occurred in a patient with neurofibromatosis type 1.

用于恶性周围神经鞘瘤的鉴别诊断的组合物

本发明涉及一种用于恶性周围神经鞘瘤(MPNST)的鉴别诊断的组合物、包含该组合物的鉴别诊断试剂盒、使用该组合物提供MPNST的鉴别诊断所需信息的方法、筛选用于预防、减轻和治疗MPNST的物质的方法等。使用本发明的能够检测蛋白质标志物的组合物具有使得能够预测和诊断患有1型神经纤维瘤病的患者是否发生恶性肿瘤的效果。

Ｓｌｉｔ−Ｒｏｂｏシステムを用いた骨折又は骨粗鬆症の予防或いは治療用組成物

【課題】Ｓｌｉｔ、ｒｏｂｏ又はその発現タンパク質を有効成分として含む骨折又は骨粗鬆症の予防或いは治療用薬学組成物の提供。【解決手段】ｓｌｉｔ１、ｓｌｉｔ２、ｓｌｉｔ３、ｒｏｂｏ１、ｒｏｂｏ２及びｖｉｌｓｅで構成された群から選択された遺伝子又はその発現タンパク質を有効成分として含有する骨折又は骨粗鬆症の予防或いは治療用薬学的組成物、前記タンパク質を含む骨折又は骨粗鬆症の発生危険予測用マーカー組成物、前記タンパク質に特異的に結合する抗体を含む骨折又は骨粗鬆症の発生危険予測用キット、及び前記タンパク質に特異的に結合する抗体を用いたｓｌｉｔタンパク質の発現水準を測定する段階を含む骨折又は骨粗鬆症の発生危険を予測するための情報提供方法。【効果】ｓｌｉｔ３は、骨折又は骨粗鬆症の予防或いは治療用組成物及び骨折又は骨粗鬆症の発生危険を予測するためのバイオマーカーとして有用に利用できる。【選択図】図６

Antibody specifically binding to lgals3bp, and use thereof

An antibody or antigen-binding fragment thereof specifically binding to galectin 3-binding protein (LGALS3BP), and a use thereof, is described. The antibody or antigen-binding fragment thereof may comprise heavy chain CDRs and light chain CDRs of specific sequences. The antibody specifically binding to LGALS3BP has been found to inhibit cancer growth and metastasis in an animal model with cancer and may be effective for alleviating or treating cancer.

Composition for improving, preventing or treating skin disease comprising induced pluripotency stem cell-derived mesenchymal stem cells pretreated with interferon gamma and exosomes derived therefrom

The present invention may provide a method for producing induced pluripotency stem cell-derived mesenchymal stem cells (IFNγ-iMSC) pretreated with interferon-gamma; induced pluripotency stem cell-derived mesenchymal stem cells pretreated with interferon-gamma prepared by the method; a pharmaceutical composition for preventing or treating skin diseases, and a cosmetic composition for preventing or improving skin diseases, comprising culture thereof or exosome (IFNγ-iMSC-exo) isolated therefrom as an active ingredient. When the composition of the present invention is used, it is possible to provide a composition for skin diseases and a stem cell therapeutic agent, which have an improved immunomodulating function over conventional mesenchymal stem cells.

Methods of inhibiting pathological angiogenesis with doppel-targeting molecules

There is provided an antibody that binds to doppel or a doppel-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region. The doppel-targeting molecules are capable of inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject.

Medical image process apparatus, medical image learning method, and medical image process method

A medical image learning method of a medical image process apparatus includes preparing a plurality of body X-ray images for learning as an input of a learning data set, preparing internal diagnostic indicator information corresponding to each of the plurality of body X-ray images for learning as a label of the learning data set, and learning an artificial neural network model using the learning data set. The internal diagnostic indicator information includes information on a cardiovascular border. The information on the cardiovascular border includes information on at least one of an aortic knob, a pulmonary conus, a left atrial appendage, an upper right cardiac border, a lower right cardiac border, a lower left cardiac border, a descending aorta, a carina, an upper end point of a diaphragm, a right pulmonary artery, a posterior cardiac border, and an anterior spinal border.

Paper-based, nucleic acid-detecting kit and method for analysis of pcr amplicon

Breast cancer diagnosis device

The present invention relates to a breast cancer diagnosis device. More particularly, the present invention relates to a breast cancer diagnosis device for early detection of the presence or absence of breast cancer lesions inside the breast of a diagnosis subject. The breast cancer diagnosis device includes: an X-ray diagnosis unit generating an X-ray image of a diagnosis subject; an optical diagnosis unit generating an optical transmission image of the diagnosis subject; and a transfer unit which is coupled to the X-ray diagnosis unit and the optical diagnosis unit to transfer all or part of the X-ray diagnosis unit and the optical diagnosis unit, and sequentially transfer all or part of the X-ray diagnosis unit or the optical diagnosis unit toward the diagnosis subject.

Alloferon Peptide and Method Using the Same

The present disclosure provides a method for treating a degenerative neuronal disease, comprising administering, to an individual suffering from neurodegenerative disease, a therapeutically effective amount of an alloferon peptide having an amino acid sequence of SEQ ID NO: 1.